Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

Running, not enrolling · Not applicable

Conditions studied: Von Hippel-Lindau Disease, Genetic Disorder

In brief

The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.

Key facts

Study ID

NCT05737602

Run by

Massachusetts General Hospital

People needed

40

Starts

2024-07-30

Expected to finish

2028-07-01

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 18+
• Confirmed diagnosis of VHL

You may not qualify if…

• Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI).
• Unwilling or unable to participate in study sessions delivered via Partners Telehealth videoconferencing.
• Participated in Phase 1 qualitative interview.

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.